July 29 (Reuters) - AstraZeneca's COVID-19 vaccine
sales more than tripled to $894 million in the second quarter
from the previous three months but shaved off 1 U.S. cent from
earnings, and the drugmaker updated its 2021 forecasts on
Thursday to include sales from its Alexion unit.
(Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout
in London)